What is Stifel Canada’s Forecast for TSE:HLS Q1 Earnings?

HLS Therapeutics Inc. (TSE:HLS) – Stock analysts at Stifel Canada issued their Q1 2025 earnings estimates for HLS Therapeutics in a research report issued on Tuesday, March 25th. Stifel Canada analyst J. Keywood forecasts that the company will post earnings of ($0.16) per share for the quarter. The consensus estimate for HLS Therapeutics’ current full-year earnings is ($0.12) per share. Stifel Canada also issued estimates for HLS Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.43) EPS.

Separately, Stifel Nicolaus increased their price objective on HLS Therapeutics from C$3.50 to C$4.00 and gave the stock a “hold” rating in a report on Wednesday.

HLS Therapeutics Trading Up 2.3 %

Shares of TSE:HLS opened at C$4.52 on Thursday. The firm has a fifty day moving average of C$4.18 and a two-hundred day moving average of C$3.80. The company has a quick ratio of 1.01, a current ratio of 1.56 and a debt-to-equity ratio of 86.50. HLS Therapeutics has a 12-month low of C$3.00 and a 12-month high of C$5.48. The firm has a market capitalization of C$100.56 million, a P/E ratio of -4.53 and a beta of 1.07.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.